Abstract
There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF-related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced-based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF-related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team-based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
Original language | English (US) |
---|---|
Article number | e021566 |
Journal | Journal of the American Heart Association |
Volume | 10 |
Issue number | 16 |
DOIs | |
State | Published - Aug 17 2021 |
Keywords
- Atrial fibrillation
- Cardiac rehabilitation
- Prevention
- Research
- Risk factors
- Sleep
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Research priorities in the secondary prevention of atrial fibrillation: A national heart, lung, and blood institute virtual workshop report'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Heart Association, Vol. 10, No. 16, e021566, 17.08.2021.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Research priorities in the secondary prevention of atrial fibrillation
T2 - A national heart, lung, and blood institute virtual workshop report
AU - Benjamin, Emelia J.
AU - Al-Khatib, Sana M.
AU - Desvigne-Nickens, Patrice
AU - Alonso, Alvaro
AU - Djoussé, Luc
AU - Forman, Daniel E.
AU - Gillis, Anne M.
AU - Hendriks, Jeroen M.L.
AU - Hills, Mellanie True
AU - Kirchhof, Paulus
AU - Link, Mark S.
AU - Marcus, Gregory M.
AU - Mehra, Reena
AU - Murray, Katherine T.
AU - Parkash, Ratika
AU - Piña, Ileana L.
AU - Redline, Susan
AU - Rienstra, Michiel
AU - Sanders, Prashanthan
AU - Somers, Virend K.
AU - Van Wagoner, David R.
AU - Wang, Paul J.
AU - Cooper, Lawton S.
AU - Go, Alan S.
N1 - Funding Information: Dr Benjamin receives research funding from US National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL128914, R01 HL092577, R01 HL141434, and U54 HL120163, NIH National Institute of Aging (NIA) grants R01 AG066010 and R01 AG066914, and American Heart Association AHA_18SFRN34110082. Dr Alonso receives research funding from US NIH, NHLBI grants K24 HL148521 and R01 HL137338, NIA R21 AG058445, and American Heart Association 16EIA26410001. Dr Djoussé receives research funding from US NIH, NIA R01 AG053325 and R01 AG053325), and NHLBI R01 HL131687. Dr Forman receives funds from the NIA through grants R01 AG060499, R01 AG058883, R01 AG051376, and P30 AG024827, and from the NIH Common Fund U01 AR071130. Dr Hendriks is supported by a Future Leader Fellowship from the National Heart Foundation of Australia. Dr Kirchhof is supported by European Union (grant agreement 633196 [CATCH ME]), European Union BigData@Heart (grant agreement EU IMI 116074), British Heart Foundation (FS/13/43/30324, PG/17/30/32961, PG/20/22/35093, and AA/18/2/34218), German Centre for Cardiovascular Research, supported by the German Ministry of Education and Research (Deutsches Zentrum für Herz-Kreislaufforschung, via a grant to Atrial Fibrillation Network [AFNET]), and Leducq Foundation. Dr Marcus receives research funding from the NIH (National Cancer Institute 75N91020C00039, National Institute of Biomedical Imaging and Bioengineering 3U2CEB021881-05S1 and subcontract related to the RADx initiative, National Institute on Alcohol Abuse and Alcoholism R01AA022222), Patient-Centered Outcomes Research Institute (CER-2017C3-9091), Tobacco-Related Disease Research Program High Impact Research Award 27IR-0027, and the Bill Funding Information: The views expressed in this article are those of the authors and do not nec-essarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; the US Preventive Services Task Force; the US Department of Health and Human Services; or the Department of Veterans Affairs. Sources of Funding Dr Benjamin receives research funding from US National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL128914, R01 HL092577, R01 HL141434, and U54 HL120163, NIH National Institute of Aging (NIA) grants R01 AG066010 and R01 AG066914, and American Heart Association AHA_18SFRN34110082. Dr Alonso receives research funding from US NIH, NHLBI grants K24 HL148521 and R01 HL137338, NIA R21 AG058445, and American Heart Association 16EIA26410001. Dr Djoussé receives research funding from US NIH, NIA R01 AG053325 and R01 AG053325), and NHLBI R01 HL131687. Dr Forman receives funds from the NIA through grants R01 AG060499, R01 AG058883, R01 AG051376, and P30 AG024827, and from the NIH Common Fund U01 AR071130. Dr Hendriks is supported by a Future Leader Fellowship from the National Heart Foundation of Australia. Dr Kirchhof is supported by European Union (grant agreement 633196 [CATCH ME]), European Union BigData@Heart (grant agreement EU IMI 116074), British Heart Foundation (FS/13/43/30324, PG/17/30/32961, PG/20/22/35093, and AA/18/2/34218), German Centre for Cardiovascular Research, supported by the German Ministry of Education and Research (Deutsches Zentrum für Herz-Kreislaufforschung, via a grant to Atrial Fibrillation Network [AFNET]), and Leducq Foundation. Dr Marcus receives research funding from the NIH (National Cancer Institute 75N91020C00039, National Institute of Biomedical Imaging and Bioengineering 3U2CEB021881-05S1 and subcontract related to the RADx initiative, National Institute on Alcohol Abuse and Alcoholism R01AA022222), Patient-Centered Outcomes Research Institute (CER-2017C3-9091), Tobacco-Related Disease Research Program High Impact Research Award 27IR-0027, and the Bill and Melinda Gates Foundation. Dr Mehra receives research funding from the American Heart Association AHA_18SFRN34170013. Dr Murray is supported by research grants: NIH HL133127 and American Heart Association 18SFRN34230125 and 20SCG35540037. Dr Parkash is supported by the Heart and Stroke Foundation of Canada, the Canadian Institute of Health Research 400660 and the Cardiac Arrhythmia Network. Dr Redline receives research funding from US NIH, NHLBI grants R35 HL135818, HL125307, HL151253, HL140412, HL125307, HL135818, HL133684, HL137192, HL036801, HL137234, HL146339, and HL153874, and NHLBI contract 75N92019C00011; National Institute of Diabetes and Digestive and Kidney Diseases grant DK107972; NIA grants AG062667, AG066137, and HL153874; and the Department of Defense A8750-18-C-0026. Dr Rienstra is supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, for Reappraisal of Atrial Fibrillation: Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilisation in the Progression of AF (RACE V) consortium, Reviving Early Diagnosis of CardioVascular Disease (RED-CVD) consortium, and Netherlands Cardiovascular Research Initiative-Artificial Intelligence consortia, and from the Dutch Heart Foundation for Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION) study. Dr Sanders is supported by Practitioner Fellowships from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia. Dr Somers is supported by NIH HL65176, NIH HL134885, and NIH HL134808. Dr Van Wagoner is supported by research grants from American Heart Association AHA_18SFRN34170442 and NIH R01 HL111314. Dr Wang is supported by the American Heart Association 20SFRN35360189 and 18SFRN34120036; and Stanford University Co-PI of BAROS (Bariatric Atrial Restoration of Sinus Rhythm), NCT04050969. Dr Go receives research funding from US NIH, NHLBI grant R01 HL142834 and National Institute of Diabetes and Digestive and Kidney Diseases R01 DK103612. Funding Information: and Melinda Gates Foundation. Dr Mehra receives research funding from the American Heart Association AHA_18SFRN34170013. Dr Murray is supported by research grants: NIH HL133127 and American Heart Association 18SFRN34230125 and 20SCG35540037. Dr Parkash is supported by the Heart and Stroke Foundation of Canada, the Canadian Institute of Health Research 400660 and the Cardiac Arrhythmia Network. Dr Redline receives research funding from US NIH, NHLBI grants R35 HL135818, HL125307, HL151253, HL140412, HL125307, HL135818, HL133684, HL137192, HL036801, HL137234, HL146339, and HL153874, and NHLBI contract 75N92019C00011; National Institute of Diabetes and Digestive and Kidney Diseases grant DK107972; NIA grants AG062667, AG066137, and HL153874; and the Department of Defense A8750-18-C-0026. Dr Rienstra is supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, for Reappraisal of Atrial Fibrillation: Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilisation in the Progression of AF (RACE V) consortium, Reviving Early Diagnosis of CardioVascular Disease (RED-CVD) consortium, and Netherlands Cardiovascular Research Initiative - Artificial Intelligence consortia, and from the Dutch Heart Foundation for Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION) study. Dr Sanders is supported by Practitioner Fellowships from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia. Dr Somers is supported by NIH HL65176, NIH HL134885, and NIH HL134808. Dr Van Wagoner is supported by research grants from American Heart Association AHA_18SFRN34170442 and NIH R01 HL111314. Dr Wang is supported by the American Heart Association 20SFRN35360189 and 18SFRN34120036; and Stanford University Co-PI of BAROS (Bariatric Atrial Restoration of Sinus Rhythm), NCT04050969. Dr Go receives research funding from US NIH, NHLBI grant R01 HL142834 and National Institute of Diabetes and Digestive and Kidney Diseases R01 DK103612. Publisher Copyright: © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2021/8/17
Y1 - 2021/8/17
N2 - There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF-related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced-based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF-related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team-based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
AB - There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF-related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced-based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF-related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team-based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
KW - Atrial fibrillation
KW - Cardiac rehabilitation
KW - Prevention
KW - Research
KW - Risk factors
KW - Sleep
UR - http://www.scopus.com/inward/record.url?scp=85113819261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113819261&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.021566
DO - 10.1161/JAHA.121.021566
M3 - Article
C2 - 34351783
AN - SCOPUS:85113819261
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 16
M1 - e021566
ER -